Real World Use and Outcomes of VASCADE Closure Device Versus Manual Compression in Patients With CFA Disease

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Total Enrollment

200 participants

Study Classification

OBSERVATIONAL

Study Start Date

2020-08-20

Study Completion Date

2021-12-01

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

To study the patient characteristics and outcomes associated with the real-world use of manual compression vs. vascular closure devices (VCDs) after common femoral artery (CFA) percutaneous access for coronary and endovascular interventions. An institutional procedural database, based on electronic medical record information will be abstracted to collect this information.

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

Feasibility and Safety of Total Percutaneous Closure of Femoral Arterial Access Sites in the Veno-arterial ECMO Patients

NCT04689451

Cardiogenic Shock Extracorporeal Membrane Oxygenation Myocarditis +4 more

UNKNOWN

Groin Complications Post Percutaneous Coronary Intervention Using Either Manual Compression or PERCLOSE Device

NCT00842179

Vascular Closure

COMPLETED

CaveoVasc System - a New Femoral Vascular Access and Closure Device

NCT02694549

Catheterization Via a Femoral Sheath ≤ 6Fr

TERMINATED NA

Characteristics Predictive of Success and Complications in the Use of Suture-Mediated Closure of Femoral Venous Access

NCT00838175

Cardiac Catheterization

UNKNOWN

The Ladera Suture-Mediated Large Bore Closure Study

NCT06851481

Vascular Closure Femoral Arteriotomy Closure

RECRUITING NA

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

The overall objective of the study will be to examine the safety and efficacy of the VASCADE closure device compared to manual compression (standard of care) to achieve hemostasis after endovascular procedures requiring access within a severely diseased CFA.

This study will be a retrospective single center review of 200 patients undergoing endovascular procedures utilizing vascular access within a severely diseased CFA between 2018 and 2020 at Yale New Haven Hospital. A random selection of patients undergoing hemostasis with manual compression (n = 100) and VASCADE vascular closure system (n = 100) will be conducted. The two groups will then be statistically compared with respect to 48-hour and 30-day safety and efficacy outcomes.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Common Femoral Artery Stenosis

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Observational Model Type

CASE_CONTROL

Study Time Perspective

RETROSPECTIVE

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

manual compression cohort

Manual compression cohort: Patients who underwent coronary or peripheral angiograms via CFA access with moderate to severe stenosis were hemostasis was achieved via manual compression

No interventions assigned to this group

VASCADE cohort

VASCADE cohort: Patients who underwent coronary or peripheral angiograms via CFA access with moderate to severe stenosis were hemostasis was achieved via VASCADE device closure

No interventions assigned to this group

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

1. 5, 6 or 7 Fr access within the CFA
2. ACT \< 300 seconds
3. Age 18 - 90 years old
4. Severe common femoral arterial disease Percent stenosis \> 50, which will be core-lab adjudicated

Exclusion Criteria

1. Ipsilateral CFA access within 30 days preceding or subsequent to the index case
2. Prior ipsilateral closure device use, other than VASCADE
3. High bleeding risk ACT \> 300 or \> 250 with IIb/IIIa inhibitor Plt \< 50K INR \> 1.7 on the day of procedure Inherent coagulopathy NOAC, warfarin, or lovenox administered within 24 hours of the procedure
4. Suspected intraluminal thrombus, dissection, pseudoaneurysm, hematoma, or AV Fistula

Minimum Eligible Age

18 Years

Maximum Eligible Age

100 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No